Amgen at TPD Summit 2026
Oct 26–29, 2026 Boston, MA ~300 attendees Website
Amgen takes part in 4 sessions at TPD Summit 2026 in Boston. It opens the plenary session on partnerships, investment and data-driven decisions, asks whether degraders are the right goal for induced proximity, and joins a panel on securing funding for the field. Another of its talks covers finding molecular glues with proteomics and deep screening.
| Organization | TPD Summit 2026 Attendance |
|---|---|
Amgen Thousand Oaks, CA | |
Global biopharmaceutical company with medicines in oncology, inflammation, cardiovascular and bone disease, and induced proximity research. | Chair Wed Oct 28 8:20am Chair’s Opening Remarks Investment, partnering & strategy Talk Wed Oct 28 9:30am Beyond Degraders: Are We Asking the Wrong Questions in Induced Proximity? Induced proximity beyond degradation Panel Wed Oct 28 10:00am Shaping Investment in Induced Proximity: Insights to Accelerate Development & Secure Funding Investment, partnering & strategy Talk Thu Oct 29 2:15pm GlueScope: Accelerating Molecular Glue Discovery through Orthogonal Proteomics & Deep Screening Screening, assays & proteomics |
Instantly find 20 buyers from Amgen
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the TPD & Induced Proximity Summit or its organizers. Submit a correction